A comprehensive view of Rx-to-OTC Switch. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Perrigo's HRA Pharma submits application to FDA to switch Opill daily birth control pill from prescription-only to OTC; if approved, Opill would be first OTC birth control pill in US, where every year 6.1 million pregnancies are unintentional

Raymond James: Perrigo's acquisition of HRA Pharma may be overlooked by investors, as HRA is expected to file application for OTC birth control pill by end-2022; in light of Roe v. Wade ruling, potential annual sales of HRA pill could hit US$100M-US$200M

Perrigo receives final FDA approval for OTC use of the Nasonex 24HR Allergy, previously available via prescription; Perrigo expects to begin offering the product later in 2022

Allergan announces LASTACAFT antihistamine eye drops with alcaftadine ophthalmic solution 0.25% now available as OTC product in 5 mL multidose bottle with 60 day supply; itchy eyes affect 40% of Americans with ocular allergies

Fitch: UK's OTC medicine market is a pioneer in terms of switching drug status from prescription to OTC, and is among most developed across Europe and globally; UK's OTC segment share of total market expected to rise to 9.1% by 2031 from 7.9% in 2021

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count